Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.54 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CD38 | P28907 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30290183 | 0.85 | HCAR3 (0.48) | GRM5S1PR1 | |
| SCHEMBL23304425 | 0.85 | HCAR3 (0.48) | GRM5S1PR1 | |
| SCHEMBL18755890 | 0.82 | GRM5 (0.56) | GRM5ANO1SMYD3KDRNPC1 | |
| SCHEMBL31633780 | 0.81 | S1PR1 (0.45) | S1PR1 | |
| SCHEMBL25088192 | 0.79 | ANO1 (0.41) | GRM5ANO1SMYD3KDRS1PR1 | |
| SCHEMBL1098419 | 0.78 | KDM4E (0.49) | SMYD3S1PR1 | |
| SCHEMBL2442535 | 0.78 | SMYD3 (0.51) | GRM5ANO1SMYD3KDRS1PR1 | |
| SCHEMBL2442538 | 0.78 | SMYD3 (0.51) | GRM5ANO1SMYD3KDRNPC1 | |
| SCHEMBL9561243 | 0.78 | NPC1 (0.55) | GRM5KDRNPC1RAB9A | |
| SCHEMBL26922153 | 0.78 | ANO1 (0.58) | GRM5ANO1KDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403137-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | GRM5 1675/4885ANO1 851/4885SMYD3 2036/4885 |
| US-12403137-B2 | Compounds and methods of use | XDH, LPXN, F12 | GRM5 332/4885ANO1 1159/4885SMYD3 1689/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | GRM5 1675/4885ANO1 851/4885SMYD3 2036/4885 |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | XDH, LPXN, F12 | GRM5 332/4885ANO1 1159/4885SMYD3 1689/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | GRM5 1675/4885ANO1 851/4885SMYD3 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.